These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 24405419)
1. Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Giannetti AM; Zheng X; Skelton NJ; Wang W; Bravo BJ; Bair KW; Baumeister T; Cheng E; Crocker L; Feng Y; Gunzner-Toste J; Ho YC; Hua R; Liederer BM; Liu Y; Ma X; O'Brien T; Oeh J; Sampath D; Shen Y; Wang C; Wang L; Wu H; Xiao Y; Yuen PW; Zak M; Zhao G; Zhao Q; Dragovich PS J Med Chem; 2014 Feb; 57(3):770-92. PubMed ID: 24405419 [TBL] [Abstract][Full Text] [Related]
2. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463 [TBL] [Abstract][Full Text] [Related]
3. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859 [TBL] [Abstract][Full Text] [Related]
4. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614 [TBL] [Abstract][Full Text] [Related]
5. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase. Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394 [TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors. Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990 [TBL] [Abstract][Full Text] [Related]
7. Structure based design of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors from a phenotypic screen. Palacios DS; Meredith E; Kawanami T; Adams C; Chen X; Darsigny V; Geno E; Palermo M; Baird D; Boynton G; Busby SA; George EL; Guy C; Hewett J; Tierney L; Thigale S; Weihofen W; Wang L; White N; Yin M; Argikar UA Bioorg Med Chem Lett; 2018 Feb; 28(3):365-370. PubMed ID: 29275937 [TBL] [Abstract][Full Text] [Related]
8. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase. Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455 [TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery of novel amide-containing nicotinamide phosphoribosyltransferase (nampt) inhibitors. Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Gunzner-Toste J; Liederer BM; Ly J; O'Brien T; Oh A; Wang L; Wang W; Xiao Y; Zak M; Zhao G; Yuen PW; Bair KW J Med Chem; 2013 Aug; 56(16):6413-33. PubMed ID: 23859118 [TBL] [Abstract][Full Text] [Related]
11. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities. Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875 [TBL] [Abstract][Full Text] [Related]
12. Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. Zheng X; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Gunzner-Toste J; Zhao G; Yuen PW; Bair KW J Med Chem; 2013 Jun; 56(12):4921-37. PubMed ID: 23617784 [TBL] [Abstract][Full Text] [Related]
13. Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methylprop-2-ynylamino]-N-(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt). Lockman JW; Murphy BR; Zigar DF; Judd WR; Slattum PM; Gao ZH; Ostanin K; Green J; McKinnon R; Terry-Lorenzo RT; Fleischer TC; Boniface JJ; Shenderovich M; Willardsen JA J Med Chem; 2010 Dec; 53(24):8734-46. PubMed ID: 21080724 [TBL] [Abstract][Full Text] [Related]
14. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. Lee MW; Sevryugina YV; Khan A; Ye SQ J Med Chem; 2012 Aug; 55(16):7290-4. PubMed ID: 22889195 [TBL] [Abstract][Full Text] [Related]
15. Discovery of trans-3-(pyridin-3-yl)acrylamide-derived sulfamides as potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors for the potential treatment of cancer. Zhang K; Ni Y; Chen J; Tu Z; Wu X; Chen D; Yao H; Jiang S Bioorg Med Chem Lett; 2019 Jun; 29(12):1502-1506. PubMed ID: 30992165 [TBL] [Abstract][Full Text] [Related]
16. Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties. Gunzner-Toste J; Zhao G; Bauer P; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Fu B; Han B; Ho YC; Kley N; Liang X; Liederer BM; Lin J; Mukadam S; O'Brien T; Oh A; Reynolds DJ; Sharma G; Skelton N; Smith CC; Sodhi J; Wang W; Wang Z; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X; Bair KW; Dragovich PS Bioorg Med Chem Lett; 2013 Jun; 23(12):3531-8. PubMed ID: 23668988 [TBL] [Abstract][Full Text] [Related]
17. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823 [TBL] [Abstract][Full Text] [Related]
18. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929 [TBL] [Abstract][Full Text] [Related]